Atossa Therapeutics(US:ATOS)2021-05-20 19:07Company Overview - Atossa Therapeutics is a clinical-stage biopharma company focused on oncology and infectious diseases, particularly breast cancer and COVID-19 [4] - As of March 31, 2021, Atossa Therapeutics had $137.6 million in cash and no debt [8] - As of May 14, 2021, the company's capital structure included 120.8 million shares of common stock [8] Drug Development Pipeline - AT-301 is a nasal spray for reducing COVID-19 symptoms, currently in Phase 2 [10] - AT-H201 is an inhalation therapy for improving lung function in COVID-19 patients, currently in Phase 1 [10] - Oral Endoxifen is in Phase 2 development for breast cancer, including a Window of Opportunity study in Australia and a Mammographic Breast Density study planned for Stockholm [10] Oral Endoxifen - Window of Opportunity (WOO) Study - Interim results from the Australian WOO study showed a 74% overall reduction in Ki-67 activity in the first 6 patients (P=.031) [22] - All patients in the WOO study had >50% reduction in Ki-67 activity and <25% Ki-67 at surgery [22] - The WOO study was halted early due to substantially positive interim results, saving time and money [21, 22] COVID-19 Therapeutics - AT-H201 is under development for moderate to severely ill COVID-19 patients to improve lung function [30] - AT-301 is a nasal spray targeting infections in the nasal passage for outpatient/home use [32] Market Opportunities - AT-H201 targets a market of >3.3 million worldwide deaths from COVID-19 [11] - AT-301 nasal spray targets a market of >163 million COVID-19 cases worldwide [11]